MedTrace Logo

Sirolimus in Previously Treated Idiopathic Multicentric Castleman Disease

NCT03933904 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2026-03-03

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to understand the impact of sirolimus on idiopathic multicentric Castleman disease.

Conditions

  • Castleman Disease
  • Castleman's Disease, Multicentric

Interventions

DRUG

Sirolimus

Sirolimus (also known as rapamycin) inhibits the mTOR protein kinase and is approved by the USA FDA for the prevention of allograft rejection in renal transplant patients ≥ 13 years of age and for the treatment of lymphangioleiomyomatosis.

Sponsors & Collaborators

Principal Investigators

  • Joshua Brandstadter, MD, PhD, MSc · University of Pennsylvania

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
2 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-25
Primary Completion
2024-06-30
Completion
2026-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03933904 on ClinicalTrials.gov